NMN at the Regulatory Threshold: When a 'Longevity' Ingredient Becomes a Novel Food - but Not an Anti-Ageing Claim - Europe's draft authorisation of beta-nicotinamide mononucleotide exposes the widening gap between biochemical plausibility, supplement regulation and clinically proven benefit

Beta-nicotinamide mononucleotide (beta-NMN) is approaching a decisive European regulatory milestone. EFSA concluded in 2026 that a chemically synthesised beta-NMN ingredient is safe at up to 300 mg/day for adults, excluding pregnant and lactating women, and is a bioavailable source of nicotinamide. In September, the European Commission submitted a draft implementing act to the Novel Food committee to authorise that ingredient under Regulation (EU) 2015/2283. Yet this is not an EU endorsement of NMN as an anti-ageing intervention. Human trials consistently show that oral NMN can alter NAD-related biomarkers, while evidence for broad metabolic, functional or longevity benefits remains limited, heterogeneous and short-term. The regulatory contrast is striking: the United States now treats NMN as eligible for dietary-supplement use subject to applicable NDI rules; Great Britain still has an application in risk assessment; Australia permits NMN in listed medicines under tightly specified conditions. This article argues that NMN is a model case for a new nutraceutical discipline under a new set of differentiated parameters, separating molecular mechanism, nutritional safety, clinical efficacy, legal market access and permissible claims before they are collapsed into a single marketing narrative